

NCT02650024 Raw comparison:

Summary:
CHIA has 29 criteria while your personal folder has 36 criteria
Total found criteria: 17/29
Total not Found: 12/29
Total Extra: 7
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Presence of chronic HCV infection based on chart   │ Presence of chronic HCV infection based on chart   │
│ review will be defined as positive for anti-HCV    │ review will be defined as positive for anti-HCV    │
│ antibody or HCV RNA at least 6 months before       │ antibody or HCV RNA at least 6 months before       │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Liver biopsy at any time showing mHAI stage 4 or   │ Liver biopsy at any time showing mHAI stage 4 or   │
│ higher fibrosis OR                                 │ higher fibrosis OR                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ FibroScan within 12 months demonstrating liver     │ FibroScan within 12 months demonstrating liver     │
│ stiffness of =9 5 kilo Pascal or                   │ stiffness of ≥9 5 kPa OR                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ NOTE If APRI and FIB-4 are discordant one of the   │ NOTE If APRI and FIB-4 are discordant one of the   │
│ other forms of fibrosis staging must be used       │ other forms of fibrosis staging must be used       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemochromatosis                                    │ Hemochromatosis                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alpha-1 antitrypsin deficiency                     │ Alpha-1 antitrypsin deficiency                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Wilson's disease                                   │ Wilson's disease                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Autoimmune hepatitis                               │ Autoimmune hepatitis                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alcoholic liver disease                            │ Alcoholic liver disease                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Drug-related liver disease                         │ Drug-related liver disease                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe NC confounding conditions (stroke head      │ Severe NC confounding conditions (stroke head      │
│ injury or developmental learning disability)       │ injury or developmental learning disability)       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Regular use of anti-inflammatory drugs             │ Regular use of anti-inflammatory drugs             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current or recent treatment with pegylated         │ Current or recent treatment with pegylated         │
│ interferon (PEG-IFN)                               │ interferon (PEG-IFN)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other active inflammatory process (major infection │ Other active inflammatory process (major infection │
│ malignancy rheumatoid arthritis/autoimmune         │ malignancy rheumatoid arthritis/autoimmune         │
│ disorder) within the prior 28 days                 │ disorder) within the prior 28 days                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled or active depression or other         │ Uncontrolled or active depression or other         │
│ psychiatric disorder that in the opinion of the    │ psychiatric disorder that in the opinion of the    │
│ site investigator might preclude adherence to      │ site investigator might preclude adherence to      │
│ study requirements or impact NC functioning and    │ study requirements or impact NC functioning and    │
│ assessments                                        │ assessments                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active drug or alcohol use or dependence that in   │ Active drug or alcohol use or dependence that in   │
│ the opinion of the site investigator would         │ the opinion of the site investigator would         │
│ interfere with adherence to study requirements     │ interfere with adherence to study requirements     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of active or acute AIDS-defining          │ Presence of active or acute AIDS-defining          │
│ opportunistic infections within 12 weeks prior to  │ opportunistic infections within 12 weeks prior to  │
│ study entry                                        │ study entry                                        │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Adult (= 18 years old) subjects with chronic genotype 1 HCV and NCI with a GDS greater than or equal │
│ to 0 5 (n=60)                                                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ For the HIV/HCV co-infected group only subjects must have HIV HIV status will be obtained through    │
│ self report Self report will be confirmed at screening using a HIV-1 point of care test In the event │
│ that point of care test and self-report are discordant then HIV status will be confirmed by a        │
│ licensed Western blot or a second antibody test                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ HIV/HCV co-infected subjects (n=12) must also have a HIV RNA measurement <50 copies/mL at the pre-   │
│ treatment visit                                                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Platelets >150 000                                                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) <10x upper limit of normal           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Creatinine clearance >30 milliliters/minute/1 73 centimeter squared                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Amiodarone                                                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ P-glycoprotein (P-gp) inducers (e g rifampin St John's wort)                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ AST to platelet ratio index (APRI) =2 0 and Fibrosis-4 (FIB-4) =3 25                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Contraindications to magnetic resonance imaging (MRI)                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Bleeding diathesis thrombocytopenia or use of anticoagulants that would contraindicate lumbar        │
│ puncture                                                                                             │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ For the HIV/HCV co-infected group only subjects must have HIV HIV status will be obtained through    │
│ self-report Self-report will be confirmed at the pretreatment visit using a HIV-1 point of care test │
│ In the event that point of care test and self-report are discordant then HIV status will be          │
│ confirmed by a licensed Western blot or a second antibody test by a method other than the initial    │
│ rapid HIV-1 and/or E/CIA or by HIV-1 antigen or plasma HIV-1 RNA viral load                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Adults (18 years old or older) with chronic HCV and NCI with a GDS greater than or equal to 0 35     │
│ (n=40)                                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Plan to receive HCV treatment from their primary care physician within 1 month of enrollment         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Any cause of liver disease other than chronic HCV infection including but not limited to the         │
│ following                                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Cirrhosis or bridging fibrosis (mHAI stages 4-6 or its equivalent)                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ APRI ≥2 0 and FIB-4 ≥3 25                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛